Ergolines as potential prolactin and mammary tumor inhibitors.
D000172:Acromegaly / Q000188:drug therapy; D000568:Amenorrhea / Q000188:drug therapy; D000818:Animals; D001971:Bromocriptine / Q000627:therapeutic use; D010064:Embryo Implantation / Q000187:drug effects; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects; D007774:Lactation / Q000187:drug effects; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy; D010902:Pituitary Gland / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000188:drug therapy; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D013329:Structure-Activity Relationship
D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin